rs1131668

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The ENST00000382264.7(IFNAR2):​c.853G>A​(p.Ala285Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.358 in 718,052 control chromosomes in the GnomAD database, including 48,370 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/17 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.35 ( 9532 hom., cov: 30)
Exomes 𝑓: 0.36 ( 38838 hom. )

Consequence

IFNAR2
ENST00000382264.7 missense

Scores

15

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 0.773

Publications

31 publications found
Variant links:
Genes affected
IFNAR2 (HGNC:5433): (interferon alpha and beta receptor subunit 2) The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. The protein belongs to the type II cytokine receptor family. Mutations in this gene are associated with Immunodeficiency 45. [provided by RefSeq, Jul 2020]
IFNAR2 Gene-Disease associations (from GenCC):
  • immunodeficiency 45
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=4.6544243E-5).
BP6
Variant 21-33262573-G-A is Benign according to our data. Variant chr21-33262573-G-A is described in ClinVar as Benign. ClinVar VariationId is 402970.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.572 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
IFNAR2NM_001289125.3 linkc.841-220G>A intron_variant Intron 8 of 8 ENST00000342136.9 NP_001276054.1 P48551-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
IFNAR2ENST00000342136.9 linkc.841-220G>A intron_variant Intron 8 of 8 1 NM_001289125.3 ENSP00000343957.5 P48551-1
IFNAR2-IL10RBENST00000433395.7 linkc.710-5821G>A intron_variant Intron 7 of 12 5 ENSP00000388223.3 H0Y3Z8

Frequencies

GnomAD3 genomes
AF:
0.350
AC:
53109
AN:
151582
Hom.:
9511
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.335
Gnomad AMI
AF:
0.246
Gnomad AMR
AF:
0.397
Gnomad ASJ
AF:
0.316
Gnomad EAS
AF:
0.591
Gnomad SAS
AF:
0.488
Gnomad FIN
AF:
0.379
Gnomad MID
AF:
0.364
Gnomad NFE
AF:
0.320
Gnomad OTH
AF:
0.339
GnomAD2 exomes
AF:
0.387
AC:
54809
AN:
141474
AF XY:
0.388
show subpopulations
Gnomad AFR exome
AF:
0.320
Gnomad AMR exome
AF:
0.445
Gnomad ASJ exome
AF:
0.316
Gnomad EAS exome
AF:
0.592
Gnomad FIN exome
AF:
0.352
Gnomad NFE exome
AF:
0.317
Gnomad OTH exome
AF:
0.345
GnomAD4 exome
AF:
0.360
AC:
203625
AN:
566350
Hom.:
38838
Cov.:
5
AF XY:
0.364
AC XY:
111628
AN XY:
306336
show subpopulations
African (AFR)
AF:
0.338
AC:
5399
AN:
15986
American (AMR)
AF:
0.441
AC:
15235
AN:
34542
Ashkenazi Jewish (ASJ)
AF:
0.317
AC:
6401
AN:
20166
East Asian (EAS)
AF:
0.566
AC:
18205
AN:
32158
South Asian (SAS)
AF:
0.464
AC:
29483
AN:
63548
European-Finnish (FIN)
AF:
0.353
AC:
12548
AN:
35582
Middle Eastern (MID)
AF:
0.394
AC:
1144
AN:
2906
European-Non Finnish (NFE)
AF:
0.315
AC:
104213
AN:
330558
Other (OTH)
AF:
0.356
AC:
10997
AN:
30904
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
7070
14141
21211
28282
35352
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
754
1508
2262
3016
3770
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.351
AC:
53174
AN:
151702
Hom.:
9532
Cov.:
30
AF XY:
0.359
AC XY:
26619
AN XY:
74068
show subpopulations
African (AFR)
AF:
0.335
AC:
13881
AN:
41380
American (AMR)
AF:
0.398
AC:
6062
AN:
15246
Ashkenazi Jewish (ASJ)
AF:
0.316
AC:
1095
AN:
3470
East Asian (EAS)
AF:
0.590
AC:
3031
AN:
5138
South Asian (SAS)
AF:
0.489
AC:
2349
AN:
4806
European-Finnish (FIN)
AF:
0.379
AC:
3959
AN:
10454
Middle Eastern (MID)
AF:
0.357
AC:
105
AN:
294
European-Non Finnish (NFE)
AF:
0.320
AC:
21749
AN:
67898
Other (OTH)
AF:
0.342
AC:
719
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1747
3495
5242
6990
8737
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
534
1068
1602
2136
2670
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.248
Hom.:
897
Bravo
AF:
0.351
TwinsUK
AF:
0.310
AC:
1149
ALSPAC
AF:
0.293
AC:
1129
ExAC
AF:
0.243
AC:
22349
Asia WGS
AF:
0.532
AC:
1845
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Jan 24, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 64% of patients studied by a panel of primary immunodeficiencies. Number of patients: 61. Only high quality variants are reported. -

Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: MAF -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Benign
-0.74
T
BayesDel_noAF
Benign
-0.70
CADD
Benign
5.5
DANN
Benign
0.82
Eigen
Benign
-0.77
Eigen_PC
Benign
-0.96
FATHMM_MKL
Benign
0.011
N
LIST_S2
Benign
0.36
.;T
MetaRNN
Benign
0.000047
T;T
MetaSVM
Benign
-0.95
T
PhyloP100
0.77
PROVEAN
Benign
0.45
N;N
REVEL
Benign
0.025
Sift
Benign
0.71
T;T
Sift4G
Benign
0.55
T;T
Polyphen
0.60
P;P
Vest4
0.098
ClinPred
0.0023
T
GERP RS
0.56
Mutation Taster
=99/1
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1131668; hg19: chr21-34634878; COSMIC: COSV51613872; COSMIC: COSV51613872; API